Initiate a Phase 2 proof-of-concept clinical trial for XEN1101 in a non-epilepsy indication
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- October 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Xenon expects to support the initiation of a Phase 2 proof-of-concept clinical trial examining XEN1101 in a non-epilepsy indication within the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company committed to initiating the trial in the first half of 2021, but filings confirm that patient enrollment for the trial did not begin until October 2021.
-
A Xenon Pharmaceuticals Inc. 10-Q filed 2021-11-10
“a Phase 2 proof-of-concept clinical trial examining XEN1101 in major depressive disorder and anhedonia is being conducted in partnership with academic collaborators at the Icahn School of Medicine at Mount Sinai, and patient enrollment was initiated in October 2021.” ✓ confirmed on the page
Market reaction: the shares moved -10.7% against the S&P 500 over the three sessions around the disclosure (9 Nov 2021 to 12 Nov 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- XEN1101 Phase 2 proof-of-concept clinical trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Xenon Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-XENE-022086 · Corrections policy